Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Holding ATOS?
Track your performance easily
ATOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $2.31
Previous Close$1.28
Volume122.38K
Average Volume (3M)606.73K
Market Cap
$162.91M
Enterprise Value$86.26M
Total Cash (Recent Filing)$74.77M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Mar 27, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding125,801,254
10 Day Avg. Volume958,261
30 Day Avg. Volume606,727
Standard Deviation0.33
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.21
Forecast
1Y Price Target
$5.83Price Target Upside350.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Atossa Therapeutics News
PremiumCompany Announcements
Atossa Therapeutics: Q3 2024 Financial Results and Updates
Ownership Overview
7.29% Insiders
7.98% Mutual Funds
0.29% Other Institutional Investors
75.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $0.70 and its highest was $2.31 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 121 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 125,801,254 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.
---
Atossa Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.83 (350.19% Upside)
$5.83 (350.19% Upside)
Blogger Sentiment
Bullish
ATOS Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.23%
12-Months-Change
Fundamentals
Return on Equity
-31.30%
Trailing 12-Months
Asset Growth
-21.85%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
---
ATOS Earnings Call
Q2 2023
0:00 / 0:00
---
ATOS Stock 12 Month Forecast
Average Price Target
$5.83
▲(350.19% Upside)
Technical Analysis
Best Analysts Covering ATOS
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+23.86%
reiterated a buy rating 15 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +23.86% per trade.
---